Low serum allopregnanolone is associated with symptoms of depression in late pregnancy.
Charlotte Hellgren, Helena Åkerud, Alkistis Skalkidou...
https://pubmed.ncbi.nlm.nih.gov/24776841/Actively Recruiting
Led by Duke University · Updated on 2026-09-03
6
Participants Needed
1
Research Sites
N/A
Total Duration
This Phase II clinical trial is studying adults aged 21 to 65 who have moderate to severe depression following a stroke. Researchers aim to find out if the oral synthetic allopregnanolone analog called zuranolone is safe and well tolerated by stroke survivors with post-stroke depression and whether it helps improve depression symptoms. The study focuses on treating depression that has lasted at least two weeks with a high score on the Hamilton Depression Rating Scale. Participants will receive 50 mg of zuranolone once daily for 14 days. This medication acts on the brains GABA receptors and is given as a pill. The trial includes only one group receiving zuranolone. During the study, participants will provide blood samples and complete mood questionnaires as well as cognitive tests. Throughout the 90-day follow-up, researchers will monitor side effects like adverse events, suicidal thoughts, and sleepiness. They will also measure changes in depression and anxiety scores at several time points including days 3, 15, and 90. The study involves regular assessments to track safety and mood improvements after treatment with zuranolone.
CONDITIONS
Allopregnanolone (Zuranolone) in Post-stroke Depression
S
Sheila Joshi
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Duke University
Lead Sponsor
American Heart Association
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Zuranolone Trial Group | Guideline-Recommended Conventional Antidepressant |
|---|---|---|
| What it is | Zuranolone is a neuroactive steroid that modulates the gamma-aminobutyric acid (GABA) receptor to potentially address symptoms of depression after stroke. It is being investigated in a single-group clinical trial in adults with moderate to severe post-stroke depression. | Conventional antidepressant pharmacotherapy, such as selective serotonin reuptake inhibitors (SSRIs), is regarded as the established first-line treatment option for post-stroke depression based on current clinical guidelines. |
| Role in trial | Primary intervention under investigation; all eligible participants receive zuranolone. | Not included as a control or comparator in the trial, but represents typical pharmacologic treatment in clinical care for similar patients. |
| Primary use | Studied to reduce symptoms of moderate to severe post-stroke depression and assess safety and response rates. | Used to treat post-stroke depression, aiming for moderate symptom reduction and functional improvement as recommended in guidelines. |
| How it is given or performed | Oral neuroactive steroid, administered as per protocol; dosing and schedule specified in the trial protocol. | Oral antidepressants, typically SSRIs or SNRIs, given once daily or as prescribed by clinical care standards. |
| Important limitations | Results for zuranolone in post-stroke depression are not yet published. The trial is small and non-randomized, so broader effectiveness and safety conclusions cannot be drawn until more participants are studied. | While conventional antidepressants are guideline-recommended, individual response varies, and side effects can include sleep disturbance, gastrointestinal upset, or sexual dysfunction. These treatments are not always effective for all cases of post-stroke depression. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 14 days
Participants take 50 mg of zuranolone orally once daily for 14 days to treat post-stroke depression.
Daily medication intake and periodic assessments
Duration - 90 days
Researchers monitor participants for side effects and changes in depression and anxiety symptoms for 90 days after starting treatment.
Assessments on days 3, 15, and 90
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Charlotte Hellgren, Helena Åkerud, Alkistis Skalkidou...
https://pubmed.ncbi.nlm.nih.gov/24776841/Fabio Pibiri, Marianela Nelson, Alessandro Guidotti...
https://pubmed.ncbi.nlm.nih.gov/18391192/Maria Giuseppina Pisu, Anna Garau, Pierluigi Olla...
https://pubmed.ncbi.nlm.nih.gov/23600845/Jiawei Xu, Yunxiang Zhou, Caochong Yan...
https://pubmed.ncbi.nlm.nih.gov/34482541/Shuyu Wang, Wenxing Zhang, Zhang Liu...
https://pubmed.ncbi.nlm.nih.gov/38292895/Lauren M Osborne, Fiona Gispen, Abanti Sanyal...
https://pubmed.ncbi.nlm.nih.gov/28278440/Nada El Husseini, Larry B Goldstein, Eric D Peterson...
https://pubmed.ncbi.nlm.nih.gov/28389192/Philipp Kinzel, Christine E Marx, Nico Sollmann...
https://pubmed.ncbi.nlm.nih.gov/32186207/Nada El Husseini, Larry B Goldstein, Eric D Peterson...
https://pubmed.ncbi.nlm.nih.gov/22461330/Tauheed Ishrat, Iqbal Sayeed, Fahim Atif...
https://pubmed.ncbi.nlm.nih.gov/20816826/Duke University
Lead Sponsor
American Heart Association
Collaborating Sponsor